# Pemetrexed Plus Tarceva as Salvage Treatment in EGFR Overexpressed Metastatic Colorectal Cancer Patients Who Were Failed After Standard Chemotherapy

> **NCT03086538** · PHASE2 · COMPLETED · sponsor: **Samsung Medical Center** · enrollment: 29 (actual)

## Conditions studied

- Colo-rectal Cancer

## Interventions

- **DRUG:** Pemetrexed
- **DRUG:** Tarceva 100Mg Tablet

## Key facts

- **NCT ID:** NCT03086538
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-30
- **Primary completion:** 2020-01-30
- **Final completion:** 2020-05-25
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2022-06-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03086538

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03086538, "Pemetrexed Plus Tarceva as Salvage Treatment in EGFR Overexpressed Metastatic Colorectal Cancer Patients Who Were Failed After Standard Chemotherapy". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT03086538. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*